secwatch.observer — SEC 8-K summary
======================================

Issuer:     NANOVIRICIDES, INC. (NNVC)
CIK:        0001379006
Form:       8-K
Filed at:   2026-05-21T10:01:46+00:00
Accession:  0001104659-26-064754
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

NanoViricides says NV-387 and NV-387-remdesivir expected to be effective against Ebola Bundibugyo strain in DRC
--------------------------------------------------------------------------------

- NV-387 is broad-spectrum antiviral entering Phase II for Mpox in DRC.
- NV-387-remdesivir is an oral formulation shown in animal models; PLOS ONE paper published.
- Encapsulation protects remdesivir from metabolism, improving efficacy per company.
- Company has a clinical site in DRC for Mpox; public health responders to decide on Ebola.
- Remdesivir was tested in prior Ebola trials but efficacy not established; antibodies approved only for Zaire strain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1379006/000110465926064754/0001104659-26-064754-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1379006/000110465926064754/tm2615268d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-064754

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer